These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23042494)

  • 1. Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCT.
    Sato M; Nakasone H; Oshima K; Ishihara Y; Wada H; Sakamoto K; Kawamura K; Ashizawa M; Machishima T; Terasako K; Kimura S; Kikuchi M; Okuda S; Tanihara A; Yamazaki R; Tanaka Y; Kanda J; Kako S; Nishida J; Kanda Y
    Bone Marrow Transplant; 2013 May; 48(5):698-702. PubMed ID: 23042494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
    Fuji S; Kim SW; Fukuda T; Mori S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Heike Y; Tobinai K; Tanosaki R; Takaue Y
    Biol Blood Marrow Transplant; 2008 May; 14(5):510-7. PubMed ID: 18410893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating IL-17 levels during the peri-transplant period as a predictor for early leukemia relapse after myeloablative allogeneic stem cell transplantation.
    Cho BS; Lim JY; Yahng SA; Lee SE; Eom KS; Kim YJ; Chung NG; Jeong DC; Lee S; Kim HJ; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Min CK
    Ann Hematol; 2012 Mar; 91(3):439-48. PubMed ID: 21894475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation.
    Akı ŞZ; Suyanı E; Bildacı Y; Çakar MK; Baysal NA; Sucak GT
    Clin Transplant; 2012; 26(5):E513-21. PubMed ID: 23061760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse.
    Min CK; Kim SY; Eom KS; Kim YJ; Kim HJ; Lee S; Kim DW; Lee JW; Min WS; Kim CC
    Bone Marrow Transplant; 2006 Mar; 37(5):493-8. PubMed ID: 16435015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantation.
    McNeer JL; Kletzel M; Rademaker A; Alford K; O'Day K; Schaefer C; Duerst R; Jacobsohn DA
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):350-7. PubMed ID: 20005964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
    Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study.
    Matsumura A; Miyazaki T; Tachibana T; Ando T; Koyama M; Koyama S; Ishii Y; Takahashi H; Nakajima Y; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S; Nakajima H
    Turk J Haematol; 2020 Feb; 37(1):20-29. PubMed ID: 31464120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM).
    Bacigalupo A; Oneto R; Bruno B; Lamparelli T; Gualandi F; Bregante S; Raiola AM; Di Grazia C; Dominietto A; Lombardi A; Frassoni F; Van Lint MT
    Bone Marrow Transplant; 2001 Dec; 28(11):1041-5. PubMed ID: 11781614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease.
    Großekatthöfer M; Güclü ED; Lawitschka A; Matthes-Martin S; Mann G; Minkov M; Peters C; Seidel MG
    Ann Hematol; 2013 Aug; 92(8):1121-8. PubMed ID: 23604429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality.
    Schots R; Kaufman L; Van Riet I; Lacor P; Trullemans F; De Waele M; Van Camp B
    Bone Marrow Transplant; 1998 Jul; 22(1):79-85. PubMed ID: 9678800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia].
    Wang Y; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Shi HX; Zhang YC; Wang JZ; Zhang XU; Chen Y; Huang XJ; Lu DP
    Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):903-6. PubMed ID: 18261271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretransplant C-reactive protein as A prognostic marker in allogeneic stem cell transplantation.
    Jordan KK; Christensen IJ; Heilmann C; Sengeløv H; Müller KG
    Scand J Immunol; 2014 Mar; 79(3):206-13. PubMed ID: 24313319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
    Shimoni A; Hardan I; Shem-Tov N; Rand A; Herscovici C; Yerushalmi R; Nagler A
    Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
    Yamamoto W; Fujii E; Matsumoto K; Yamamoto E; Aoki J; Tanaka M; Ishigatsubo Y; Kanamori H
    Int J Hematol; 2016 Apr; 103(4):444-52. PubMed ID: 26791379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial liver involvement in acute GVHD is predictive for nonrelapse mortality.
    Robin M; Porcher R; de Castro R; Fisher G; de Latour RP; Ribaud P; Petropoulou AD; Rocha V; Devergie A; Mary JY; Socié G
    Transplantation; 2009 Nov; 88(9):1131-6. PubMed ID: 19898210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning.
    DeCook LJ; Thoma M; Huneke T; Johnson ND; Wiegand RA; Patnaik MM; Litzow MR; Hogan WJ; Porrata LF; Holtan SG
    Bone Marrow Transplant; 2013 May; 48(5):708-14. PubMed ID: 23103674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.